Home Newsfeeds Morgan Stanley Maintains Underweight on General Mills, Raises Price Target to $66

Morgan Stanley Maintains Underweight on General Mills, Raises Price Target to $66

Morgan Stanley analyst Pamela Kaufman maintains General Mills (NYSE:GIS) with a Underweight and raises the price target from $56 to $66.

byBenzinga Newsdesk

July 1, 2022

1 minute read

Morgan Stanley analyst Pamela Kaufman maintains General Mills (NYSE:GIS) with a Underweight and raises the price target from $56 to $66.

News

Mannatech Launches Superfood Greens And Reds At MannaFest 2022

By Benzinga Newsdesk

September 28, 11:38 AM

Global health and wellness company Mannatech, Incorporated (NASDAQ:MTEX) just announced the launch of its new product, Superfood Greens and Reds. It was revealed in front of a live and virtual crowd on

MTEX

Ozempic’s Surging Demand Has Novo Nordisk Restricting It in Europe, Plus An Older Generation Diabetes Drug: What’s Next?

By Vandana Singh

November 21, 4:30 PM

Novo Nordisk A/S (NYSE: NVO) plans to limit starter kit supplies of Ozempic (semaglutide) in Europe and reduce the distribution of Victoza (liraglutide), aiming to bolster Ozempic's production, which has experienced a

NVO

Mirum Pharmaceuticals Priced 3.478M Share Public Offering of Common Stock @$23/Share

By Charles Gross

August 10, 5:19 AM

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced the pricing of its previously announced underwritten public offering of 3,478,261 shares of its common stock at a price to the public of $23.00 per share.

MIRM

Wedbush Reiterates Outperform on Geron, Maintains $6 Price Target

By Benzinga Newsdesk

March 17, 8:14 AM

Wedbush analyst Robert Driscoll reiterates Geron (NASDAQ:GERN) with a Outperform and maintains $6 price target.

GERN

Morgan Stanley Maintains Underweight on General Mills, Raises Price Target to $66

Related Posts

Mannatech Launches Superfood Greens And Reds At MannaFest 2022

Ozempic’s Surging Demand Has Novo Nordisk Restricting It in Europe, Plus An Older Generation Diabetes Drug: What’s Next?

Mirum Pharmaceuticals Priced 3.478M Share Public Offering of Common Stock @$23/Share

Wedbush Reiterates Outperform on Geron, Maintains $6 Price Target